1. Home
  2. TRUP vs IMCR Comparison

TRUP vs IMCR Comparison

Compare TRUP & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trupanion Inc.

TRUP

Trupanion Inc.

HOLD

Current Price

$34.13

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$37.35

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRUP
IMCR
Founded
2000
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
TRUP
IMCR
Price
$34.13
$37.35
Analyst Decision
Buy
Buy
Analyst Count
3
9
Target Price
$56.33
$67.00
AVG Volume (30 Days)
504.5K
323.1K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$1,399,759,000.00
$379,590,000.00
Revenue This Year
$13.17
$30.11
Revenue Next Year
$7.90
$8.89
P/E Ratio
$97.56
N/A
Revenue Growth
12.50
28.11
52 Week Low
$31.00
$23.15
52 Week High
$57.89
$40.53

Technical Indicators

Market Signals
Indicator
TRUP
IMCR
Relative Strength Index (RSI) 28.71 54.88
Support Level $34.74 $38.23
Resistance Level $36.62 $40.53
Average True Range (ATR) 1.37 1.49
MACD -0.15 0.04
Stochastic Oscillator 9.13 49.44

Price Performance

Historical Comparison
TRUP
IMCR

About TRUP Trupanion Inc.

Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: